New Delhi: Government has received responses from around 400 drug manufacturers so far regarding data on essential medicines as part of efforts to decide their prices under the new drug pricing policy.
"We have sent letters to drug manufacturers in states of Maharashtra, Himachal Pradesh, Rajasthan, Gujarat and Andhra Pradesh. We have already received around 400 replies from these states," National Pharmaceutical Pricing Authority (NPPA) Chairman C P Singh told reporters.
The drug price regulator has asked pharmaceutical companies to submit complete data related to essential medicines in order to fix the prices of these medicines.
NPPA has also asked pharma associations to ask their respective members to submit data so that prices of 348 drugs listed under National List of Essential Medicines (NLEM) could be fixed in time.
Singh said that NPPA is approaching drug makers in phases and also taking the help of state drug offices to send letters to drug companies across various states.
"... We had issued letters close to 4,000 manufacturers but due to some problem in addresses, nearly half of the letters have come back to us. Now, we are getting addresses from state drug offices to send these letters," he said.
"We hope to hear from them in the next 10-15 days after that we would assess the situation as what steps need to be taken in this regard," he added.
In order to fix prices of NLEM drugs, NPPA requires data relating to production, moving annual turnover value prices at stockist level as on May 31, 2012, the regulator said in the letter to pharma companies.
As per the National Pharmaceutical Pricing Policy-2012 (NPPP-2012), the prices of drugs under NLEM are to be fixed by the government, primarily based on the prices at stockist level and the market share of specific formulations.
The NPPP-2012, which was approved by the Cabinet on November 22, 2012, has been notified on December 7, 2012, fixes ceiling price of NLEM medicines, by adopting the simple average price of all the brands having market share of more than and equal to 1 percent of the total market turnover of that medicine.